ACT Community Health Forum

ACT coordinates monthly Community Health Forums from September to March bringing community members and preeminent professional and community experts together to learn about current trends affecting people living with HIV. Topics are determined in consultation with feedback from forum attendees and with input from the project’s advisory committee.

The current featured forum is:

Please download this flyer at the bottom of this page

Topics are determined in consultation with feedback from forum attendees and with input from the project’s advisory committee.

ACT Community Health Forum Videos

ACT partners with The Ontario HIV Treatment Network (OHTN) to record three of our dynamic forums every year.
PrEP: The HIV Prevention Pill

With James Wilton, Epidemiologist, Ontario HIV Treatment Network; Consultant CATIE
(March 2016)

Video Summary Notes:
PrEP was the single most sought after topic by participants in the Community Health Forum surveys, and has proven to be one of the most talked about HIV prevention topics in recent years. James Wilton, an epidemiologist with the Ontario HIV Treatment Network (OHTN), provided the ACT Community Health Forum an overview of the recent state of PrEP research, implementation and rollout in Canada; just after the federal government announced approval of Truvada for PrEP in February. This video was recorded at the OHTN offices to enhance quality and clarity. This video does not discuss issues related to the criminalization of HIV non-disclosure. For more in-depth information on this topic please visit CATIE at: http://www.catie.ca/en/prevention/social-and-legal-issues#legal or the Canadian HIV Legal network’s site at: http://www.aidslaw.ca/site/our-work/criminalization/.

Additional PrEP Links
Detailed information on PrEP from ACT: http://www.actoronto.org/prep
Summary from ACT of how new technologies and techniques are changing HIV prevention: http://www.hivnow.ca/
In depth resources on PrEP from CATIE, Canada’s source for HIV and hepatitis C information: http://www.catie.ca/en/prep (également disponible en français)

Video Topics Index: Start: What is daily oral PrEP?; 1:40 min Approval of Truvada for PrEP around the world; 2:08 min How effective is PrEP?; 4:00 Specific sexual activities and PrEP effectiveness; 4:46 min IPrEX Open Label Study; 5:30 min Proud Study (UK); 6:24 min Safety of PrEP and side effects; 7:14 min Drug resistance; 7:57 min Regular medical supervision needed for PrEP; 8:17 min Future types of PrEP in development; 10:03 min State of implementing PrEP use and clinical guidelines; 10:44 min Regulatory approval of PrEP; 11:23 min Accessing PrEP in Ontario; 11:35 min Barriers to accessing PrEP; 12:11 min Future access to PrEP; 12:33 min Presentation summary.


Undetectable: Exploring Viral Load as HIV Prevention

With James Wilton, Epidemiologist, Ontario HIV Treatment Network; Consultant CATIE
(March 2016)

Video Summary Notes:
“Can someone be infected if the other person has an undetectable viral load?” That’s the question that researchers are racing to document, along with a host of other transmission related questions. James Wilton, an epidemiologist with the Ontario HIV Treatment Network (OHTN), tackles the issue with a review of the landmark conclusive research in the field, and the resulting clinical recommendations that physicians can use with clients to implement this prevention technique in Canada. This video was recorded at the OHTN offices to enhance quality and clarity.

Additional Links on Treating HIV to Prevent HIV Transmission
Summary from ACT of how new technologies and techniques are changing HIV prevention including HIV treatment and HIV prevention: http://www.hivnow.ca/
In depth resources on HIV Treatment to prevent HIV transmission from CATIE, Canada’s source for HIV and hepatitis C information: http://www.catie.ca/en/prep (également disponible en français)

Video Topics Index: Start: What is Viral Load?; 1:04 min Changes in Viral Load; 1:52 min How Viral load is important for Exposure to HIV; 2:27 min Antiretroviral treatment can drop viral load to undetectable levels; 3:49 min The HPTN 052 RCT Study (2011) – first conclusive evidence of lower viral load means less risk of transmission; 5:14 min What about viral load and transmission via anal sex? (PARTNER Study Interim Analysis - 2014); 6:04 min Opposites Attract Study; 6:35 min Considerations to keep in mind interpreting the HPTN 052 and the PARTNER studies; 7:34 min Understanding Transmissions that did occur; 8:09 min Quebec Consensus Statement and other Guidelines for using lowered viral load as HIV prevention; 9:13 Summary of Presentation.

Global HIV Treatment Research: 2015 in Review – Presented December 16, 2015

With Dr Sharon Walmsley, MSc, MD, FRCPC

As a hands-on research scientist at the Toronto Hospital Research Institute, and Co-Director of the Canadian HIV Trials Network, Dr. Walmsley is well placed to review and comment on international advances in HIV research.

The Biggest HIV Treatment News of 2015: the START Study – When to start HIV Treatments

Video Topics Index: START Study Design: 2.20 min; Study Participants: 4.40 min; Study Results: 7.15 min; What happened to people who did not go on treatment right away?: 10.12 min; Conclusion with Kaplain-Meier based Analysis: 10.53 min; Tuberculosis: 12.00 min; Lymphoma 12.28 min; KS:12.44 min; PCP: 12.56 min; Cancer (not AIDS related): 13.26 min; Concluding Summary of START Study: 13.40 min



Treatment Options and the New Treatment Trends to Watch

Video Topics Index: Do we need new drugs?: 0 min; Maturation Inhibitors 1.00 min; Attachment Inhibitors: 2.07 min; Challenging the idea of using three HIV treatment class of drugs: 3.34 min; MARCH Study (Maraviroc) 9.20 min; What to Start Treatment With - Comparing Medical Guidelines and Integrase Inhibitors: 11.10 min; Why start with an integrase inhibitors (Former Standard: Efavirenz/Atripla): 13.30 min; Suicide: 14.40; Boosted Protease Inhibitors: 16.20 min; Integrase Inhibitor Tolerance: 17.20 min; What to Start with Summary: 18.00 min; Women/WAVES Study: 18.28 min; Women/ARIA Study: 19.59 min; Tenofavir (Tenofavir Alafenamide – TAF):20.36 min; TAF vs. TDF Study: 22.52 min; Switching to TAF: 26.00 min; STRIIVING Study (Triumeq): 28.35 min; Thinking About Switching?: 30.35 min



Looking Forward to 2016 in HIV Treatment News

Video Topics Index: Treatment Cascade: 0 min; Lipodystrophy: 2.05 min; Cancer & HIV: 4.00 min; Hep C & HIV: 6.54 min; PrEP & PEP: 8.26 min; Summary Remarks: 11.37 min


HIV & Hepatitis C Co-infection - Presented March 19, 2015

With Dr David Wong, FRCPC, Hepatologist, University Health Network & Andrew Eaton, Group Programming Coordinator, ACT.

Hep C Transmission, Diagnosis, Treatment, Coinfection with HIV and Medical Advances

Video Topics Index: Comparing Hep C and HIV:0 min; What does the Liver Do? & Liver Failure: 3.15 min; Spectrum of Liver Desease: 7.24 min; Risk for Liver Disease if you are living with HIV: 8.14 min; Sexual Transmission of Hep C if you are living with HIV: 11.26 min; Treatments for Hep C if you are living with HIV: 12.58 min; New Hep C Treatments: 14.06 min



Community Supports for Hep C and HIV Coinfection

Video Topics Index: Four Types of Supports: 0 min; OHTN Rapid Response Inquiry on what Models of Service Exist: 2.39 min; OHTN Rapid Response Findings: 4.00 min; Problems with Coercion in Service Provision: 8.24 min


ACT offers a support group for people living with HIV and hepatitis C. To register email Andrew at aeaton@actoronto.org.
HIV & Aging – Presented November 19, 2014

With Kate Murzin & John McCullagh

Video Topics Index: New infections in older adults: 3.10 min; Prevalence of HIV in Older Adults: 5.52 min; Four Distinct Groups of Older Adults and HIV: 7.29 min; Questions people ask themselves as they age: 25.05 min; Video Case Study 1: Sexual Health and Living with HIV for older Adults with actors Joanne Lindsay/Dr Gordon Arbess: 32.22 min; Video Topic Summary: 43.52 min; Relevant Services: 45.50 min; Video Case Study 2: Living with HIV and Residential Care with actors John McCullagh/ Kate Murzin: 53.44 min; Video Topic Summary: 1.04.06 min; Relevant Services: 1.06.20 min; Research on HIV and Older Adults: 1.19.50 min; Summary: 1.20.55 min





For more information, please e-mail Rui Pires or call 416-340-8484 ext. 264.
CHF_DEC2016.pdfCHF_DEC2016.pdf

CHF_DEC2016.pdf210 (Kbytes)